R
Richard N. Bergman
Researcher at Cedars-Sinai Medical Center
Publications - 489
Citations - 97005
Richard N. Bergman is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 130, co-authored 477 publications receiving 91718 citations. Previous affiliations of Richard N. Bergman include University of Southern California & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
The genetic basis of glucose homeostasis.
TL;DR: Knowing the genetic basis of glucose homeostasis will facilitate the development of more directed therapies for prevention and treatment of diabetes and other diseases associated with disordered glucose metabolism.
Journal ArticleDOI
Intravenous Insulin Infusion to Simulate Subcutaneous Absorption: Bioavailability and Metabolic Sequelae
TL;DR: It is concluded that, in dogs, insulin delivered subcutaneously in the interscapular area is not significantly degraded before absorption, resulting in metabolic effects equal to intravenous insulin infusion of equivalent dose.
Insulin Clearance and the Incidence of Type 2 Diabetes in Hispanics and
C. Christine Lee,Steven M. Haffner,Lynne E. Wagenknecht,Carlos Lorenzo,Jill M. Norris,Richard N. Bergman,Darko Stefanovski,Andrea Anderson,Jerome I. Rotter,Mark O. Goodarzi,Anthony J. Hanley +10 more
TL;DR: The data showed that lower MCRI predicts the incidence of type 2 diabetes, and was associated with a higher risk of incident diabetes after adjusting for demographics, lifestyle factors, HDL cholesterol, indexes of obesity and adiposity, and insulin secretion.
Posted ContentDOI
Mortality Attributed to COVID-19 in High-Altitude Populations
TL;DR: Altitude is associated with COVID-19 mortality in men younger than 65 years and among Mexican subjects <65 years old, the risk of death was higher in those living at [≥]2,000 m vs. <1,500 m and no association was found among women.
Journal ArticleDOI
Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes
Viorica Ionut,Orison O. Woolcott,Hasmik Mkrtchyan,Darko Stefanovski,Morvarid Kabir,Malini S. Iyer,Huiwen Liu,Ana Valeria B. Castro,Qiang Wu,Josiane L. Broussard,Cathryn M. Kolka,Isaac Asare-Bediako,Richard N. Bergman +12 more
TL;DR: In pre-diabetic canines, 12-week exenatide treatment improved β-cell function but not glucose tolerance or insulin sensitivity, and partial beneficial metabolic effects of exen atide alone on an animal model of pre- diabetes are demonstrated.